Chapter 13. The Drug Discovery Process
- Ralph Rapley2,
- Stuart Harbron3
Published Online: 27 SEP 2005
DOI: 10.1002/0470020202.ch13
Copyright © 2004 John Wiley & Sons, Ltd
Book Title
Molecular Analysis and Genome Discovery
Additional Information
How to Cite
Solari, R. (2005) The Drug Discovery Process, in Molecular Analysis and Genome Discovery (eds R. Rapley and S. Harbron), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470020202.ch13
Editor Information
- 2
University of Hertfordshire, UK
- 3
The Enzyme Technology Consultancy, UK
Publication History
- Published Online: 27 SEP 2005
- Published Print: 23 APR 2004
ISBN Information
Print ISBN: 9780471499190
Online ISBN: 9780470020203
- Summary
- Chapter
Keywords:
- high-throughput screening (HTS);
- new chemical entities (NCEs);
- green fluorescent protein (GFP);
- differential gene expression (DGE);
- clinical trial exemption (CTX);
- maximum tolerated dose (MTD);
- black-box assays;
- pharmacogenomics
Summary
This chapter contains sections titled:
Introduction
The process
Target discovery
Target validation
Discovery of chemical leads
Hits to leads
Lead molecular optimization
Lead to development candidate
Biological candidates
Pre-clinical development
Development issues for biological drugs
Clinical trials
Intellectual property
Summary
References
Appendix